Illumina, Inc.
Health
Performance
7.6
Risk
Sell
Buy
Curious about the Scores? Learn more.

Illumina, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

07.02.2026
On shaky ground. Struggling to find a clear direction.
03.02.2026
Momentum tanked. Clearly underperforming.
31.01.2026
Trouble brewing. Volatility and pressure rising.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.
ILMN
Illumina, Inc.
119.84
-10.40%
7.6
Sell
Buy
Illumina, Inc.

Illumina, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Illumina, Inc. do? Business model and key facts

Get the full picture of Illumina, Inc.: what it builds, where it operates, and how it makes money.

Illumina, Inc. Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 8970

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

shop
Company facts
Jacob Thaysen
CEO
8970
Employees worldwide
shop
Performance
14.03%
Last 12 months
-72.69%
Last 5 years
shop
Growth
$4,37B
Revenue year
$-1.223.000.000
Net income
shop
Valuation
$18,29B
Market Cap
-17.37
Price/Earnings Ratio

Stocks related to Illumina, Inc.

Selected based on industry alignment and relative market positioning.

EXAS
Exact Sciences Corporation
102.07
+0.51%
6.9
Sell
Buy
Exact Sciences Corporation
DGX
Quest Diagnostics Incorporated
192.00
-0.83%
2.2
Sell
Buy
Quest Diagnostics Incorporated
WAT
Waters Corporation
383.50
+1.17%
5.0
Sell
Buy
Waters Corporation
MEDP
Medpace Holdings, Inc.
542.04
+0.14%
4.8
Sell
Buy
Medpace Holdings, Inc.
GH
Guardant Health, Inc.
101.85
+3.55%
8.7
Sell
Buy
Guardant Health, Inc.

Illumina, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.